Yasin Sezgin
Overview
Explore the profile of Yasin Sezgin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
10
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Urun M, Guner G, Sezgin Y, Sakin A, Kilickap S
Med Sci Monit
. 2024 Dec;
30:e946751.
PMID: 39690723
BACKGROUND This retrospective study from a single center included 289 patients diagnosed with advanced non-small cell lung cancer (NSCLC) between 2010 to 2017 and aimed to evaluate the effects of...
2.
Karhan O, Ileri S, Urakci Z, Arvas H, Karakas Kilic D, Sezgin Y, et al.
Oncology
. 2024 Nov;
:1-10.
PMID: 39586283
Introduction: Conflicting evidence exists regarding the concurrent use of cyclin-dependent kinase (CDK) 4/6 inhibitors and proton pump inhibitors (PPIs) in the treatment of breast cancer. This study aimed to investigate...
3.
Sezgin Y, Bora E, Arda D, Uyanikgil Y, Erbas O
Acta Cir Bras
. 2024 Oct;
39:e396924.
PMID: 39356936
Purpose: Tamoxifen, a widely used drug for breast cancer treatment, is associated with adverse effects on the liver, including the development of fatty liver. This study aimed to investigate the...
4.
Urun M, Guner G, Sezgin Y, Uysal E, Sakin A, Kilickap S
Med Sci Monit
. 2024 Sep;
30:e945752.
PMID: 39256975
BACKGROUND The advanced lung cancer inflammation index (ALI) is regarded as a potential indicator of systemic inflammation. This retrospective study aimed to evaluate the prognostic role of the ALI in...
5.
Sezgin Y, Karhan O, Ileri S, Ebinc S, Tunc S, Urakci Z
J Coll Physicians Surg Pak
. 2024 Aug;
34(8):904-909.
PMID: 39113507
Objective: To evaluate the efficiency of pemetrexed cisplatin in comparison with gemcitabine cisplatin and to validate the EORTC (European Organisation for Research and Treatment of Cancer) prognostic score in combination...
6.
Karhan O, Secmeler S, Sezgin Y, Ileri S, Yerlikaya H
Future Oncol
. 2023 May;
19(14):983-989.
PMID: 37170860
To compare the clinicopathological features and time to reach treatment of patients with breast cancer among Syrian refugees (SR) and Turkish citizens (TC). Retrospective data from 2014 to 2021 were...
7.
Ebinc S, Oruc Z, Sezgin Y, Karhan O, Bilen E, Yerlikaya H, et al.
Future Oncol
. 2022 Sep;
18(30):3399-3408.
PMID: 36069377
The rates of and the factors influencing HER2 discordance in patients receiving neoadjuvant therapy for breast cancer are investigated. This study retrospectively examines the rates of HER2 and hormone receptor...
8.
Survival impact of optimal treatment for elderly patients with colorectal cancer: A real world study
Akdeniz N, Kucukoner M, Kaplan M, Urakci Z, Sezgin Y, Karhan O, et al.
Indian J Cancer
. 2021 Aug;
58(4):539-544.
PMID: 34380826
Background: In this real-life practice study, we aimed to find whether elderly colorectal cancer (CRC) patients in our center were treated optimally and also if this has an effect on...
9.
Akdeniz N, Kucukoner M, Kaplan M, Urakci Z, Karhan O, Sezgin Y, et al.
Int J Clin Oncol
. 2020 Aug;
25(12):2015-2024.
PMID: 32797321
Purpose: The optimal chemotherapy regimen for concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) remains unclear. Cisplatin-etoposide regimen related toxicity is high, weekly regimens have been investigating. We...
10.
Karaagac M, Sezgin Y, Karakurt Eryilmaz M, Araz M, Kaplan M, Artac M
J Oncol Pharm Pract
. 2020 Feb;
26(7):1657-1666.
PMID: 32063110
Introduction: Soft tissue sarcomas are a heterogeneous and rare group of cancers with a short median overall survival despite the chemotherapy. Pazopanib has approval for the treatment of advanced soft...